Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6917 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's Days Payable falls into.
Andros Pharmaceuticals Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Andros Pharmaceuticals Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Andros Pharmaceuticals Co (ROCO:6917) has a Days Payable of 5.32 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Andros Pharmaceuticals Co and its competitors. This is 44% below median its historical median of 9.46. Over the past decade, Andros Pharmaceuticals Co's Days Payable has ranged from 3.71 to 19.18. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #669 out of 701 companies in the Biotechnology industry, placing it in the top 95.4%.
Is Andros Pharmaceuticals Co's Days Payable too high?
Andros Pharmaceuticals Co's current Days Payable of 5.32 is 44% below median its 10-year median of 9.46. Over the past 10 years, this metric has ranged from a low of 3.71 to a high of 19.18. The Biotechnology industry median Days Payable is 112.84. Andros Pharmaceuticals Co's value of 5.32 is 95.3% below this industry median. Based on the distribution chart, Andros Pharmaceuticals Co ranks #669 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #669 out of 701 companies for Days Payable. This places Andros Pharmaceuticals Co in the lower half of its industry. The industry median Days Payable is 112.84. Andros Pharmaceuticals Co's value of 5.32 is 95.3% below this benchmark. Historically, Andros Pharmaceuticals Co's own Days Payable has ranged from 3.71 to 19.18 over the past decade. While the company's 10-year median is 9.46 vs. the industry median of 112.84, Andros Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Andros Pharmaceuticals Co's current Days Payable of 5.32 is 95.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current Days Payable is 5.32, which is 44% below median its own 10-year median of 9.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Days Payable is 5.32, which is 44% below median its 10-year median of 9.46 and 95.3% below the Biotechnology industry median of 112.84. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Days Payable is 5.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
Days Payable: 5.32 (44% below median its 10-year median of 9.46)
GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
Industry Position: 95.3% below the Biotechnology median (#669 of 701)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score
Get the complete analysis for ROCO:6917
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
